We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account

Research and Development

Home » Topics » Pharmaceuticals » Research and Development
  • May 20, 2022

    NASEM Calls for Action by FDA, NIH to Improve Trial Diversity

    In a congressionally mandated report on diversity in clinical trials, the National Academies of Sciences, Engineering and Medicine (NASEM) recommends the FDA require drug sponsors to file an in-depth recruitment strategy, either before or with their investigational new drug (IND) or investigational device exemption (IDE) applications, that details how they intend to make their trial population reflective of the disease or condition’s demographics.
  • May 18, 2022

    Sanofi’s Sarclisa Treatment Combination Shows More Positive Data on Multiple Myeloma

    In March 2021, early results from the same trial supported the FDA approval of Sarclisa when combined with Kyprolis and dexamethasone.
  • May 17, 2022

    BMS’ Opdivo and Yervoy Combination Fails to Meet Key Endpoint in Urothelial Cancer

    Bristol Myers Squibb (BMS) said that its late-stage trial of Opdivo (nivolumab) plus Yervoy (ipilimumab) did not meet its goal of improving overall survival compared with standard-of-care treatment in certain patients with untreated unresectable or metastatic urothelial cancer.
Read More
  • May 17, 2022

    AstraZeneca’s Albuterol/Budesonide Combo Asthma Drug Drops Flare-ups in Study

  • May 16, 2022

    Gilead’s Lenacapavir Deeply Suppresses HIV Load in Multidrug-Resistant Patients

  • May 13, 2022

    AbbVie’s JAK Inhibitor Rinvoq Scores in Crohn’s Maintenance Therapy Trial

  • May 12, 2022

    Roche Posts Another Tiragolumab Chemotherapy Flop

  • May 12, 2022

    AstraZeneca, Sanofi Pooled Data Bolster RSV Win for Nirsevimab

  • May 11, 2022

    UK Study Shows Promising Data for Fourth COVID-19 Vaccine Shot

  • May 10, 2022

    Pfizer Offers Real-World Data on Ibrance in Metastatic Breast Cancer

  • May 10, 2022

    FDA Finds Switching Levothyroxine Generics Does Not Affect Hormone Levels

  • May 9, 2022

    UC Researchers Examine Effects of Pfizer’s Paxlovid on ‘Long COVID’ Patients

  • May 9, 2022

    Marinus Restarts Study After Reformulating Problematic Drug

Read More

Products

  • Radhika rajagopalan 600green

    CDER’s Priorities for 2022: What You Must Know About New Guidance and Program Plans – Webinar Recording/Transcript

    $287.00
  • Kellie combs josh oyster 500blue

    Communicating Directly with Consumers on Social Media: What You Must Know About FDA and FTC Ad and Promo Rules – Webinar Recording/Transcript

    $287.00
  • Proving comparability in cell and gene therapy 500

    Proving Comparability in Cell and Gene Therapy Development: Untangling FDA Requirements

    $397.00
  • Davidlchesney aqua500

    Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections – Webinar Recording/Transcript

    $287.00
More Products

Events

  • 24May

    Quality Culture: You Can’t Improve What You Don’t Measure — Practical, Innovative Diagnostic Tool Allows Companies to Measure and Improve Their Quality Culture

  • 09Jun

    How to Standardize your Lab Investigation Process: Increase Efficiency and Reduce Risk with a Consistent Process

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

More

Pages

  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing